Philips Trilogy Evo, O2, International


650,000.00 760,340.00

Transitioning to the future. Advancing respiratory care today

When you’re treating respiratory patients, it’s hard to know what today will bring. One thing is for sure, transitions can occur often,
and for any number of reasons. Conditions escalate. Patients are moved. Therapy modes are changed. Each time, patient care is at
risk of disruption, causing needless stress on the team. That’s why Philips Respironics is making a transition of its own — to an even
brighter future in respiratory care.
Philips Respironics is the #1 respiratory* brand† of choice by U.S. pulmonary physicians. And, we’re unveiling a
new platform of innovative Trilogy Evo ventilators. Bridging ground-breaking technology with improved data flow,
Trilogy Evo helps benefit a broad spectrum of patients, from newborns to adults. Trilogy Evo is the only portable
life support ventilator platform designed to stay with patients and provide consistent therapy and monitoring as
they change care environments and when their condition changes. So when transitions do occur, disruptions are
minimized; and the level of respiratory care remains intact. Making today a much better day for clinicians, caregivers

Applications for use
Trilogy Evo can monitor lung parameters, without a hold
maneuver, while promoting the patient’s respiratory muscle
activation, which has shown to be beneficial to weaning and the
liberation of patients from the ventilator17-19.
Having access to estimations of the lung parameters in the
home care setting is new and best practices will still need to be
determined. There are however, a number of ways that these
parameters could be utilized including:
• Long term trending of lung parameters to see if any
pathophysiology changes are occurring (i.e.. decrease in
compliance as fibrosis worsens or increase in resistance
corresponding to inflammation in the airways).
• Assistance in determining the appropriateness of initial
ventilator settings during therapy titration.
• Assistance in evaluating changes in ventilator prescription
settings as they impact respiratory mechanics and patient
ventilator synchrony.
• Additional information to help determine any short-term
response to pharmacological treatments (Dyn R and Dyn C).
• Indication of an accumulation of secretions in the airway
requiring intervention (increase in Dyn R) (See Figure 1).
• Indication of dynamic hyperinflation due to ventilator
patient asynchrony such as limited expiratory time,
expiratory air flow limitation or hyperventilation (AutoPEEP).
• Assistance to use protective lung strategies and minimize
lung injury (Dyn Pplat).
• Assistance to ensure open lung ventilation preventing
atelectasis and hyperextension during mechanical
ventilation (Dyn C), e.g. by indicating the need of a lung
recruitment maneuver.

Trilogy Trilogy Evo
Spontaneous (S) PSV
Spontaneous Timed (ST) S/T
Timed (T) A/C-PC (with trigger off)
Pressure Control (PC) A/C-PC
Pressure Control SIMV (PC-SIMV) SIMV-PC
Assist Control (AC) A/C-VC
Control Ventilation (CV) A/C-VC (with trigger off)
Synchronized Intermittent
Mandatory Ventilation (SIMV)
PC – Mouth Piece Ventilation (MPV) MPV-PC
AC – Mouth Piece Ventilation (MPV) MPV-VC
The future of respiratory
care is here.
To learn more about Trilogy Evo, talk to
your Philips Sales Representative, or
call on 1800 258 678

Out of stock



    EMI at 0% cost (only on credit card swipe)

    Note: 2 Years warranty for device


    Connect with Philips